Lateral Port‐Site Hernia Following Robot‐Assisted Radical Prostatectomy: Case Reports and Proposal of a Preventive Technique Authors: Akihiro Kojima, Motohiro Fujiwara, Takumasa Amemiya, Ayaka Koizumi, Junpei Takashima, Masayasu Urushibara, Touko Asano, Hideto Kano, Kazuhiro Ishizaka, Minato Yokoyama Published: 2026 ABSTRACT ABSTRACTIntroductionPort‐site hernia is a rare but serious complication that can occur after robot‐assisted radical prostatectomy and requires surgical repair.Case PresentationIn 2024, we experienced two cases of port‐site hernia after robot‐assisted radical prostatectomy. In response, we developed a preventive technique to reduce the risk of port‐site hernia. Here, we present one of the two cases of port‐site hernia after robot‐assisted radical prostatectomy and a case in which port‐site hernia did not occur after receiving the new preventive technique. We also describe the preventive method currently employed at our institution, where an anti‐adhesion agent is applied to the removal site of a 12‐mm port and closure suture involves fascia without peritoneum. This technique is simple, safe, and applicable to all patients.ConclusionWe developed a new and simple procedure to prevent port‐site hernia based on our experience. Our method may have the potential to effectively prevent its occurrence. Introduction Robot‐Assisted Radical Prostatectomy (RARP) has become widely adopted as a standard minimally invasive procedure for localized prostate cancer [1, 2]. Port‐site hernia (PSH) is known as a rare but serious complication of RARP. In RARP, PSH typically occurs at the site of a 12‐mm port [3, 4], while PSH has also been reported, although rarely, at smaller port sites [5]. In 2024, we performed 73 cases of RARP. Of these, two cases of PSH occurred. Therefore, we implemented our own preventive measure against PSH. In this article, we report one of the two cases of PSH after RARP, and a case in which PSH did not occur after receiving the new preventive technique. Case Presentation Case 1 An 81‐year‐old man with BMI 21.9 kg/m2 and no history of abdominal surgery underwent prostate biopsy in 2015 for PSA of 5.9 ng/mL. The biopsy revealed a Gleason score of 3 + 3, and active surveillance was initiated for cT2cN0M0. In July 2024, surveillance biopsy revealed progression to Gleason score of 4 + 3. Due to concurrent severe lower urinary tract symptoms, transperitoneal anterior RARP was performed in October 2024. Port placement included a far‐right 12‐mm bladeless trocar (Figure 1). Nerve‐sparing and lymph node dissection were omitted. Port placement in RARP. Four ports for the da Vinci system, and 5‐ and 12‐mm ports for the assistant. The 12‐mm port was carefully closed, including sufficient peritoneum and fascia. On postoperative day 5, vomiting occurred. Abdominal X‐ray indicated small intestine obstruction, and a nasogastric tube was placed. However, his symptoms showed little improvement. On day 8, contrast‐enhanced CT revealed small intestine obstruction caused by PSH at the 12‐mm port site (Figure 2). Emergency surgery revealed that intestinal serosa was adherent to the peritoneal suture and the intestine was incarcerated at the 12‐mm port site. After reduction, the fascia and peritoneum were resutured. The patient was discharged 8 days later following an uneventful recovery. Contrast‐enhanced abdominal CT showing a PSH in case 1. (A) Axial view; (B) Coronal view. Based on the findings from Case 1, we implemented PSH prevention using an anti‐adhesion barrier at our institution, as described below. We present a representative case in which this method was applied. Case 2 An 81‐year‐old man with BMI 21.9 kg/m2 and no history of abdominal surgery underwent transperitoneal anterior RARP for cT2aN0M0 prostate cancer. Nerve‐sparing surgery was performed, whereas pelvic lymph node dissection was omitted. An anti‐adhesion barrier (Seprafilm) was applied to the 12‐mm port site (Figure 3A) instead of suturing the peritoneum, followed by closure of the fascia. Application of antiadhesive agents on the removal site of a 12‐mm port for the prevention of PSH during RARP. (A) Seprafilm membrane in Case 2, (B) AdSpray gel, and (C) Interceed sheet. Yellow arrowheads indicate the application sites. No postoperative complications including PSH were observed during 11 months follow‐up. Discussion While RARP has largely replaced open surgery due to perioperative benefits, it introduces unique complications like PSH, reported in 0.2%–4.8% of cases [6, 7, 8]. According to Tonouchi et al. [9], PSH is classified into three types. The early‐onset type involves dehiscence of the fascia and peritoneum and occurs in the early postoperative period, often with bowel obstruction. The late‐onset type involves fascial dehiscence with an intact peritoneum forming the hernia sac and develops several months after surgery. The special type involves complete abdominal wall dehiscence with protrusion of bowel or omentum without a hernia sac. In both of our cases, PSH occurred within several days after surgery and is therefore classified as the early‐onset type. Although PSH at smaller port sites has been reported, PSH most commonly occurs at the 12‐mm port site due to three factors [3, 10]. First, the 12‐mm trocar is larger than the other trocars, resulting in more extensive damage to the fascia and muscle layers. Helgstrand et al. reported that ports larger than 10 mm in diameter are more likely to cause PSH [11]. Thus, avoiding the use of a 12‐mm port may be worth considering [12]. Second, bladed trocars are utilized to facilitate smooth insertion of this larger‐diameter port. However, this approach can enlarge the damage of the fascia and muscle layers, which may increase the risk of PSH [13]. Third, a 12‐mm trocar in the lateral abdominal wall may tend to be placed obliquely rather than vertically to avoid injury to intra‐abdominal organs. The oblique insertion of a 12‐mm trocar may enlarge the peritoneal defect and diminish structural support provided by the fascia and muscles. Additionally, peritoneal closure of the obliquely inserted 12‐mm port site would be complicated. Standard layer‐to‐layer closure is effective but skill‐dependent. We had previously experienced a case in which insufficient suturing might have led to the development of PSH. In Case 1, we emphasized secure suturing based on this experience; however, this resulted in inadvertent bowel entrapment, which caused PSH. On the basis of these observations, we devised a new method for PSH prevention that can be performed more safely. Assistive devices (e.g., Endo Close, Carter‐Thomason) facilitate closure but carry risks of visceral injury or difficulty in thin patients [14, 15]. While the preventive benefit of peritoneal closure remains debated, preventing visceral adhesion to the abdominal wall defect is crucial [16, 17]. To address this, as in Case 2, we adopted the application of bioresorbable anti‐adhesion agents to the 12‐mm port site at the time of removal of the 12‐mm port. This simple method prevents adhesions—a precursor to hernia incarceration—without the risk of needle injury associated with peritoneal suturing. Since adhesion of intra‐abdominal organs to the abdominal wall takes several days to develop, the use of anti‐adhesive agents during this period may help prevent it. Thereafter, facilitated regeneration of mesothelium would yield long‐term anti‐adhesion effect [18]. Several materials have been developed for this purpose, including hyaluronate and carboxymethylcellulose (Seprafilm), N‐hydroxysuccinimide‐modified carboxymethyl dextrin (AdSpray Figure 3B), and oxidized regenerated cellulose (Interceed Figure 3C), all of which are bioresorbable barriers designed to reduce postoperative adhesion formation. Our method is simple and safe, as an anti‐adhesion agent is applied to the removal site of a 12‐mm port and closure suture involves fascia without peritoneum. Since December 2024, we have applied this technique with fascial‐only closure in 21 cases, with no PSH occurrences over a median 12‐week follow‐up. No written consent has been obtained from the patients as there is no patient‐identifiable data included. This novel approach offers a safe and potentially effective strategy to prevent PSH and its complications. Although rare, in patients who receive anti‐adhesion agents, foreign body reactions can lead to granuloma formation [19]; therefore, caution is warranted. However, no such events occurred in our 21 cases. We also recognize that PSH prevention at ports other than 12 mm may be necessary, but this remains an area for future investigation. We reported a case of PSH after RARP, and a case in which a new and simple PSH prevention technique was applied and PSH did not occur after RARP. Although the number of cases and the follow‐up period are limited, and the effectiveness remains uncertain, we will continue to accumulate cases in the future. PSH is a serious complication which requires additional surgery, and our method may have the potential to effectively prevent its occurrence. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.